This report examines the clinical utility of genotyping for SLCO1B1 variants in pediatric or adult patients needing treatment with a statin to reduce low-density lipoprotein cholesterol. The evidence for the use of genetic testing is evaluated with respect to selecting statin type or dose in order to improve statin prescribing and patient adherence, and to avoid adverse events such as skeletal muscle pain.
If you have a Hayes login, click here to view the full report on the Knowledge Center.